Le Lézard
Classified in: Health
Subjects: TRI, FDA

SofWave Medical's Low-divergence Ultrasound Technology Has Received FDA Clearance for the Aesthetic Treatment of Facial Lines and Wrinkles


YOQNEAM, Israel, Sept. 16, 2019 /PRNewswire/ -- Sofwave Medical Ltd., an emerging aesthetic device company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Sofwave system. The Sofwave device is indicated for use as a non-invasive aesthetic treatment to improve facial lines and wrinkles.

The 510(k) clearance was supported by a blinded study of 59 subjects, demonstrating the safety and performance of the Sofwave System for non-invasive treatment to improve facial lines and wrinkles. The trial was led by Principal Investigators Dr. Roy Geronemus, New York and Dr. Arielle Kauvar, New York.

According to investigators' evaluation, 86% of the subjects demonstrated improvement in wrinkle appearance of at least one Elastosis Score (-1ES), while the blinded reviewers identified correctly the pre- and post-treatment photographs for 78% of the treated subjects.

Dr. Roy Geronemus stated, "The Sofwave technology represents the next-generation in aesthetic devices and is exactly what my patients are looking for ? non-invasive, minimal downtime, and with favorable results. The Sofwave device has great potential to fill this void".

Dr. Kauvar added, "Our patients were surprised they could achieve such obvious results after only one treatment. The Sofwave procedure is tolerated very well and it appears that the treatment depth is ideal for improving aging skin".

Dr. Shimon Eckhouse, Sofwave Medical's Chairman of the Board, stated, "Our patented, low-divergence fractional ultrasound technology is a simple solution based on sophisticated science with proven efficacy to treat facial lines and wrinkles. He added, "I am excited to once again bring innovative aesthetic devices to the market."

Louis Scafuri, Sofwave Medical's CEO said, "Receiving FDA clearance for the Sofwave technology is an important milestone for the company as it opens our product to the large market in the United States. Our breakthrough non-invasive ultrasound technology targets a growing customer base of patients who are looking to reduce their wrinkles and facial lines, but did not wish to consider surgery. We believe that our device addresses this demand across broad demographics" 

Following FDA clearance, the company will launch marketing and sales activities in the United States. For this purpose, the company has already established an office in the US, which will be the base for all sales, marketing, clinical and customer support activities for the US market.

About SofWave Medical Ltd.

SofWave Medical Ltd. implements a novel approach to wrinkle reduction using proprietary Fractional Ultrasound. SofWave Medical's breakthrough technology brings a new option to non-invasive aesthetic treatments, providing physicians with smart yet simple, effective and safe aesthetic solutions for their patients.

The company was founded in 2015 by a multidisciplinary team of engineers, physicists and experienced professionals in the aesthetics market. The corporate, R&D, and manufacturing headquarters for SofWave Medical are located in Israel. The company also has offices in California, U.S.A. 

Contact:
Mrs. Dafna Katz,
Chief Marketing Officer,
SofWave Medical
dafna@sofwave.com

 

SOURCE SofWave Medical Ltd.


These press releases may also interest you

at 18:20
bluebird bio, Inc. and Bristol-Myers Squibb announced updated safety and efficacy results from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-targeted chimeric antigen receptor (CAR) T cell therapy being studied in patients...

at 18:20
Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today presented topline data from the ASCERTAIN phase 3 trial of the orally administered fixed dose combination of cedazuridine and...

at 17:50
Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase 1 study of its bivalent T cell...

at 17:40
Welltower Inc. announces that on December 24, 2019, it is redeeming all of the outstanding 3.35% Senior Notes due November 25, 2020 (the "Notes") issued by HCN Canadian Holdings-1 LP, its wholly-owned subsidiary, in accordance with the terms of the...

at 17:20
Quest Diagnostics Incorporated , the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest...

at 17:20
Bariatric Surgery Devices (General Surgery) - Global Market Analysis and Forecast Model Read the full report: https://www.reportlinker.com/p05830908/?utm_source=PRN Summary Bariatric Surgery Devices (General Surgery) - Global Market Analysis and...



News published on 16 september 2019 at 09:00 and distributed by: